SCI Pharmtech Osake

SCI Pharmtech EBITDA

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä SCI Pharmtech (4119.TW) 9.8.2026 päivämäärällä on 155,25 M TWD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli 198,29 M TWD — muutos −21,71 % (matalampi).

EBITDA

155,25 MTWD

YoY

−21,71%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä SCI Pharmtech on 2026 155,25 M TWD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä SCI Pharmtech oli 2025 198,29 M TWD. Se laskee −21,71% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

SCI Pharmtech Osakeanalyysi

Mitä SCI Pharmtech tekee? SCI Pharmtech Inc is a leading company in the pharmaceutical industry based in Zhejiang, China. The company was founded in 2003 and has since grown continuously. Today, the company employs over 100 employees and has become a key player in the global supply chain of pharmaceutical raw materials and intermediates. SCI Pharmtech Inc's business model is based on the development and production of high-quality pharmaceutical intermediates and active pharmaceutical ingredients, as well as the manufacturing of custom chemicals. The company specializes in the production and distribution process, offering its customers a comprehensive range of products that meet the highest quality and safety standards. SCI Pharmtech Inc is divided into various divisions, each specializing in specific product categories. The main divisions are API (Active Pharmaceutical Ingredients), intermediates, and custom synthesis. The API division produces active pharmaceutical ingredients for the pharmaceutical industry, which serve as the basis for drug manufacturing. The intermediates division offers pharmaceutical intermediates used in the synthesis of active pharmaceutical ingredients. The custom synthesis division provides tailored synthesis processes for customers in need of specific chemicals or intermediates. SCI Pharmtech Inc's product portfolio includes Acetamidomalonate, Carbamazepine, and Codergocrine Mesylate, among others. The company also offers custom synthesis services, involving complex chemical syntheses and innovative technologies. SCI Pharmtech Inc places great emphasis on quality and safety. The company operates according to international standards, including GMP (Good Manufacturing Practice), ISO (International Standards Organization), and CE (Conformité Européenne). SCI Pharmtech Inc's products undergo stringent quality controls to ensure compliance with the strict regulations of global pharmaceutical regulatory authorities. Another important concern of SCI Pharmtech Inc is sustainability. The company has developed a sustainable business strategy aimed at minimizing its environmental impact and conserving resources. This includes implementing efficient production processes, reducing energy consumption and CO2 emissions, as well as promoting environmental awareness among employees and customers. Overall, SCI Pharmtech Inc is a dynamic and innovative company specializing in the production of pharmaceutical intermediates and active pharmaceutical ingredients. The company takes pride in offering high-quality products that meet the highest quality and safety standards. Through its sustainable business strategy and adherence to international standards, SCI Pharmtech Inc has achieved an excellent reputation in the pharmaceutical industry and strengthened its presence in the global market. SCI Pharmtech on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset SCI Pharmtech osakkeesta

Yhtiön SCI Pharmtech EBITDA (Tulos ennen korkoja, veroja ja poistoja) on 155,25 M TWD vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä SCI Pharmtech muuttui arvosta 198,29 M TWD arvoon 155,25 M TWD, mikä edustaa −21,71 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) SCI Pharmtech:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n TWD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n SCI Pharmtech historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — SCI Pharmtech

Kaikki tunnusluvut — SCI Pharmtech